Journal: Journal of Pharmacokinetics and Pharmacodynamics

Article Title: Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates

doi: 10.1007/s10928-023-09867-7

Figure Lengend Snippet: The effects of treating culture human hepatocytes with enzalutamide, M2, or prototypical inducers on CYP and P-gp mRNA levels

Article Snippet: The volume of distribution was predicted using the Simcyp built-in methods (Method 2 for enzalutamide and Method 1 for M2) with slight modification in enzalutamide using the K p scalar to obtain clinically observed volume of distribution [ ].

Techniques:

Journal: Journal of Pharmacokinetics and Pharmacodynamics

Article Title: Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates

doi: 10.1007/s10928-023-09867-7

Figure Lengend Snippet: Inhibitory effect of enzalutamide on 3 H-digoxin (1 µmol/L) permeation across control and MDR1-expressing cell monolayers

Article Snippet: The volume of distribution was predicted using the Simcyp built-in methods (Method 2 for enzalutamide and Method 1 for M2) with slight modification in enzalutamide using the K p scalar to obtain clinically observed volume of distribution [ ].

Techniques: Control, Concentration Assay

Journal: Journal of Pharmacokinetics and Pharmacodynamics

Article Title: Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates

doi: 10.1007/s10928-023-09867-7

Figure Lengend Snippet: Parameters for enzalutamide and M2 PBPK models

Article Snippet: The volume of distribution was predicted using the Simcyp built-in methods (Method 2 for enzalutamide and Method 1 for M2) with slight modification in enzalutamide using the K p scalar to obtain clinically observed volume of distribution [ ].

Techniques: Binding Assay, Molecular Weight, In Silico, Clinical Proteomics, Permeability, Formulation

Journal: Journal of Pharmacokinetics and Pharmacodynamics

Article Title: Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates

doi: 10.1007/s10928-023-09867-7

Figure Lengend Snippet: Observed and simulated plasma concentration–time profiles of enzalutamide and M2: ( A , B ) enzalutamide data after single 160 mg dose in linear and semi-log scales; ( C , D ) M2 data after single 160 mg dose in linear and semi-log scales; ( E , F ) enzalutamide data after multiple 160 mg doses in full-time scale and extracting 1176 to 1200 h; ( G , H ) M2 data after multiple 160 mg doses in full-time scale and extracting 1176 to 1200 h. The data shown are simulated mean (solid line), simulated 5th and 95th percentiles (dashed lines), observed mean (filled circles), and observed individual (open circles)

Article Snippet: The volume of distribution was predicted using the Simcyp built-in methods (Method 2 for enzalutamide and Method 1 for M2) with slight modification in enzalutamide using the K p scalar to obtain clinically observed volume of distribution [ ].

Techniques: Clinical Proteomics, Concentration Assay

Journal: Journal of Pharmacokinetics and Pharmacodynamics

Article Title: Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates

doi: 10.1007/s10928-023-09867-7

Figure Lengend Snippet: Observed and simulated plasma concentration–time profiles of enzalutamide after ( A ) single and ( B ) multiple doses at several dose levels. The data shown are simulated mean (lines) and observed mean (markers)

Article Snippet: The volume of distribution was predicted using the Simcyp built-in methods (Method 2 for enzalutamide and Method 1 for M2) with slight modification in enzalutamide using the K p scalar to obtain clinically observed volume of distribution [ ].

Techniques: Clinical Proteomics, Concentration Assay

Journal: Journal of Pharmacokinetics and Pharmacodynamics

Article Title: Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates

doi: 10.1007/s10928-023-09867-7

Figure Lengend Snippet: Observed and simulated AUC and C max ratios of midazolam and digoxin in presence or absence of multiple 160 mg doses of enzalutamide

Article Snippet: The volume of distribution was predicted using the Simcyp built-in methods (Method 2 for enzalutamide and Method 1 for M2) with slight modification in enzalutamide using the K p scalar to obtain clinically observed volume of distribution [ ].

Techniques:

Journal: Journal of Pharmacokinetics and Pharmacodynamics

Article Title: Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates

doi: 10.1007/s10928-023-09867-7

Figure Lengend Snippet: Observed and simulated plasma concentration–time profiles of digoxin in ( A ) absence and ( B ) presence of enzalutamide. The data shown are simulated mean (solid line), simulated 5th and 95th percentiles (dashed lines), observed mean (filled circles), and observed individual (open circles)

Article Snippet: The volume of distribution was predicted using the Simcyp built-in methods (Method 2 for enzalutamide and Method 1 for M2) with slight modification in enzalutamide using the K p scalar to obtain clinically observed volume of distribution [ ].

Techniques: Clinical Proteomics, Concentration Assay

Journal: Journal of Pharmacokinetics and Pharmacodynamics

Article Title: Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates

doi: 10.1007/s10928-023-09867-7

Figure Lengend Snippet: Simulated AUC and C max ratios of apixaban and rivaroxaban in presence to absence of 160 mg multiple dose of enzalutamide

Article Snippet: The volume of distribution was predicted using the Simcyp built-in methods (Method 2 for enzalutamide and Method 1 for M2) with slight modification in enzalutamide using the K p scalar to obtain clinically observed volume of distribution [ ].

Techniques: